Bladder cancer: imperatives for personalized medicine

Area of Science:

• Urology
• Oncology
• Molecular Pathology

Background:

• Urothelial carcinoma incidence is declining in developed nations due to regulations but rising globally.
• The disease follows a two-pathway model: FGFR3-mutated non-muscle-invasive papillary tumors and p53/Rb-deficient invasive tumors.
• The latter pathway presents a high risk of mortality.

Purpose of the Study:

• To review current understanding of urothelial carcinoma molecular pathways.
• To highlight therapeutic needs for non-muscle-invasive and muscle-invasive disease.
• To emphasize the need for research into novel therapeutics and multidisciplinary collaboration.

Main Methods:

• Review of existing literature on urothelial carcinoma.
• Analysis of molecular pathways (FGFR3, Ras, p53, Rb).
• Discussion of current and needed therapeutic strategies.

Main Results:

• Two distinct molecular pathways identified: FGFR3/Ras and p53/Rb.
• Non-muscle-invasive disease has low progression risk, while invasive disease has high mortality.
• Current treatments include intravesical therapies, surgery, and neoadjuvant chemotherapy.

Conclusions:

• Optimized intravesical therapies and timely cystectomy are crucial for high-risk non-muscle-invasive disease.
• Surgery is standard for muscle-invasive disease; neoadjuvant chemotherapy benefits a subset.
• Further research into molecular subtypes and experimental therapeutics is essential for progress.